All Posts | Links Medicus - Free Medical News & Perspective

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

9 Nov, 2021 | 01:46h | UTC

Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic – JAMA Internal Medicine

Author Interview: Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Results With Persistent Physical Symptoms – JAMA Internal Medicine

Commentaries: Expert reaction to study looking at the association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms – Science Media Centre

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

Commentary on Twitter

Except for anosmia, persistent symptoms after COVID-19 may be more related to the belief of having had #COVID19 than to actual SARS-Co-V2 infection. Clinicians and researchers should also consider general mechanisms that may not be specific to #SARSCoV2 https://t.co/IdSh5GhdQ6

— JAMA Internal Medicine (@JAMAInternalMed) November 8, 2021

How protein-based COVID vaccines could change the pandemic.

9 Nov, 2021 | 01:41h | UTC

How protein-based COVID vaccines could change the pandemic – Nature

Review: Antineutrophil cytoplasmic antibody-associated interstitial lung disease.

10 Nov, 2021 | 06:46h | UTC

Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review – European Respiratory Review

We can be confident there have been far more than 5 million global Covid deaths – “Estimating ‘excess’ fatalities, a more robust analysis method, puts the pandemic’s grim toll between 10m and 19m people”.

9 Nov, 2021 | 01:43h | UTC

We can be confident there have been far more than 5 million global Covid deaths – The Guardian

Global Covid-19 deaths surpass five million.

Effects of the Covid-19 pandemic on life expectancy and premature mortality in 2020 – this time series analysis showed there were more than 28 million excess years of life lost in 2020 in 31 countries.

Under-reporting of deaths limits our understanding of true burden of covid-19.

Study shows COVID-19 has caused the biggest decrease in life expectancy since World War II.

Just how do deaths due to COVID-19 stack up?

Tracking excess mortality across countries during the COVID-19 pandemic with the World Mortality Dataset.

Exploring the gap between excess mortality and COVID-19 deaths in 67 countries.

Report: Three new estimates of India’s all-cause excess mortality during the COVID-19 Pandemic – pandemic death toll estimated to be between 3.4 million and 4.9 million excess deaths.

COVID-19 has caused 6.9 million deaths globally, more than double what official reports show

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.

9 Nov, 2021 | 01:44h | UTC

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging.

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance

Actions to transform USPSTF methods to mitigate systemic racism in clinical preventive services.

9 Nov, 2021 | 01:24h | UTC

Actions to Transform US Preventive Services Task Force Methods to Mitigate Systemic Racism in Clinical Preventive Services – JAMA

Commentary: USPSTF Proposes Strategies to Mitigate Racism in Preventive Care – HealthDay

Not all Covid waves look the same. Here’s a snapshot of the Delta surge.

9 Nov, 2021 | 01:28h | UTC

Not all Covid waves look the same. Here’s a snapshot of the Delta surge – STAT

Commentary on Twitter

If you know someone on the fence about vaccination, show them this https://t.co/ndPLhpLlh4 pic.twitter.com/L6RLwHyGCi

— David Juurlink (@DavidJuurlink) November 8, 2021

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.

9 Nov, 2021 | 01:31h | UTC

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines – The Conversation

Systematic Review: Exercise‐based cardiac rehabilitation for coronary heart disease.

9 Nov, 2021 | 01:21h | UTC

Summary: Exercise-based rehabilitation for coronary heart disease – Cochrane Library

Original Study: Exercise‐based cardiac rehabilitation for coronary heart disease – Cochrane Library

Choosing Wisely: Nine pediatric otolaryngology recommendations.

9 Nov, 2021 | 01:09h | UTC

Choosing Wisely Canada – pediatric otolaryngology recommendations – Journal of Otolaryngology – Head & Neck Surgery

See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada

Global Consensus Statement: Principles of environmentally-sustainable anesthesia.

9 Nov, 2021 | 01:22h | UTC

Principles of environmentally-sustainable anaesthesia: a global consensus statement from the World Federation of Societies of Anaesthesiologists – Anaesthesia

Environmental and Occupational Considerations of Anesthesia: A Narrative Review and Update.

Working toward the triple bottom line in surgery to limit the impact of surgery on the environment

Effects Of Surgery On A Warming Planet: Can Anesthesia Go Green? – NPR

Anaesthetic gases, climate change, and sustainable practice – The Lancet Planetary Health

Greenhouse gases: the choice of volatile anesthetic does matter – Canadian Journal of Anesthesiology

People, planet and profits: the case for greening operating rooms – Canadian Medical Association Journal

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.

9 Nov, 2021 | 01:17h | UTC

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Perspective | Why scientific journal authorship practices make no sense “et al”.

9 Nov, 2021 | 01:07h | UTC

Why scientific journal authorship practices make no sense et al. – Science

Consensus statement on measures to promote equitable authorship in the publication of research from international partnerships.

Editorial: Authorship and Publication Matters: Credit and Credibility.

Opinion: No More First Authors, no More Last Authors

The authorship rows that sour scientific collaborations.

Systematic Review | Management of High-Need, High-Cost Patients.

9 Nov, 2021 | 01:20h | UTC

Management of High-Need, High-Cost Patients: A “Best Fit” Framework Synthesis, Realist Review, and Systematic Review – Agency for Healthcare Research and Quality

Lessons from a Superb Clinical Trial – commentary on a recent randomized trial testing left atrial appendage occlusion during cardiac surgery to prevent stroke.

9 Nov, 2021 | 01:08h | UTC

Lessons from a Superb Clinical Trial – by Dr. John Mandrola

Original Study: #ACC21 – Practice Changing RCT: In patients with atrial fibrillation (75% maintained on anticoagulation), left atrial appendage occlusion during cardiac surgery reduces the incidence of stroke and systemic embolism (4.8 vs. 7.0%) in the following years.

Choosing Wisely for Thyroid Conditions: Ten things clinicians and patients should question – “Do not order thyroid ultrasound for nodule detection in patients without thyroid anatomic anomalies on clinical examination”.

9 Nov, 2021 | 01:11h | UTC

Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors.

9 Nov, 2021 | 01:04h | UTC

Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors – JCO Oncology Practice

Commentary on Twitter

#Neuroendocrine tumors are heterogeneous with a complex treatment landscape. This #JCOOP Clinical Review discusses optimal management of #NET and key patient/tumor characteristics that can guide treatment selection https://t.co/zZF36E93w8 pic.twitter.com/2xqwOlwIvw

— Journal of Clinical Oncology (@JCO_ASCO) October 28, 2021

FDA Pooled Analysis: Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant.

9 Nov, 2021 | 01:05h | UTC

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm

— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

Commentary on Twitter (thread – click for more)

Pfizer’s oral protease inhibitor PF-07321332 for #COVID19 Reduced Risk of Hospitalization or Death from 6.7% (41/612) to 1.0% (6/607) when starting within 5 days of symptom onset.
10 vs 0 deaths. #idtwitter https://t.co/ZAIm6Y5mAt

— David Boulware, MD MPH (@boulware_dr) November 5, 2021

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.

7 Nov, 2021 | 20:29h | UTC

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination – Clinical Infectious Diseases

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.

7 Nov, 2021 | 20:31h | UTC

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

Viewpoint | Children and COVID-19 in schools.

7 Nov, 2021 | 20:24h | UTC

Children and COVID-19 in schools – Science

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

CDC Report: Schools without mask requirements were more likely to have Covid-19 outbreaks.

Perspective | Schools have begun mass testing for COVID-19. But hurdles and uncertainties remain.

COVID and schools: the evidence for reopening safely.

COVID studies note online learning stress, fewer cases in schools with protocols

[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.

7 Nov, 2021 | 20:32h | UTC

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

7 Nov, 2021 | 20:18h | UTC

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Oral pill as safe, efficacious as conventional treatment for anemia in patients with kidney disease – Brigham and Women’s Hospital

Commentary on Twitter

In this phase 3 clinical trial, daprodustat was effective as a treatment for anemia in patients with CKD who were undergoing maintenance hemodialysis or peritoneal dialysis. #KidneyWk https://t.co/ykzSsUlJci pic.twitter.com/0zdlMyOlTf

— NEJM (@NEJM) November 5, 2021

Stay Updated in Your Specialty